Phase 3 Trial

vTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes

Staff Reporter March 4, 2024 0

vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to...

BioVie’s NE3107 Demonstrates Potential Improvements in Motor and Non-motor Symptoms for Parkinson’s Disease Patients and May Be Realigning Physiological Processes for Alzheimer’s Patients in Data to be Presented at the International Conference on Alzheimer’s and Parkinson’s Diseases 2024

Staff Reporter March 2, 2024 0

BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological...

Seladelpar medication for primary biliary cholangitis

The New England Journal of Medicine Publishes Positive Phase 3 RESPONSE Data of CymaBay’s Seladelpar in Primary Biliary Cholangitis

Staff Reporter February 22, 2024 0

CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today...

LUMAKRAS and Vectibix Phase 3 Trial Results

AMGEN PRESENTS NEW LUMAKRAS® (SOTORASIB) PLUS VECTIBIX® (PANITUMUMAB) DATA IN PATIENTS WITH KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER

Staff Reporter October 23, 2023 0

Amgen (NASDAQ:AMGN) today announced data from the global Phase 3 CodeBreaK 300 trial evaluating two doses of LUMAKRAS® (sotorasib) (960 mg or...

Phase 3 Trial

vTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes

BioVie’s NE3107 Demonstrates Potential Improvements in Motor and Non-motor Symptoms for Parkinson’s Disease Patients and May Be Realigning Physiological Processes for Alzheimer’s Patients in Data to be Presented at the International Conference on Alzheimer’s and Parkinson’s Diseases 2024

The New England Journal of Medicine Publishes Positive Phase 3 RESPONSE Data of CymaBay’s Seladelpar in Primary Biliary Cholangitis

AMGEN PRESENTS NEW LUMAKRAS® (SOTORASIB) PLUS VECTIBIX® (PANITUMUMAB) DATA IN PATIENTS WITH KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER

Sculpt Clinics Introduces New Laser Hair Removal Technology

HEAL Foundation Announces Healthcare CSR Summit & Awards in New Delhi

Apsara Ice Creams to launch Muskaan initiative on its 53rd anniversary

Milann Fertility Center Celebrates World Breastfeeding Week with ‘Milann’s Embrace’ Initiative

DCN Dx to Showcase New Technologies at NextGen Dx 2024

Interesting Stories For You